Search results
Results from the WOW.Com Content Network
According to the results of the present study, the administration of acarbose in patients with MetS can lead to weight loss, abdominal obesity reduction, and decreased levels of inflammatory and cardiovascular markers, including CRP, EFT, and IMT, and increased HDL in patients.
Acarbose, especially in combination with the low calorie diet and exercise, seems to lose weight effectively in obese and overweight patients in communities that have a high carbohydrate intake (like Persian diet). Keywords: Acarbose, clinical trial, non-diabetics obese, weight loss.
Weight Loss. The effect of acarbose on weight loss has also been a research target. In an analysis of post-marketing data of 67,682 patients, the data revealed acarbose to decrease body weight significantly, independent of baseline body weight.
Some studies have shown that acarbose also produces a weight-loss effect by increasing glucagon-like peptide 1 (GLP-1). The positive effect of acarbose on GLP-1, and increasing evidence that it provides cardiovascular protection, suggests that acarbose may again be considered among the first-choice antidiabetic agents, as it was in the 1990s.
Due to the above, we believe acarbose has the potential effect of reducing blood pressure and facilitating weight loss. Our included articles are RCTs, with good baseline similarity, and our meta-analysis produced promising results.
In higher doses, acarbose even caused a dramatic loss in weight (Fig 10). Many studies have reported a beneficial effect of alpha glucosidase inhibitors on bodyweight in humans (9, 11, 20-22), although the effect was usually reported as “moderate.”
This post-hoc analysis showed that acarbose treatment reduces body weight independent of glycemic control status but dependent on baseline body weight. 1. Introduction.